publication venue for
- Disease Characteristics and Outcomes of 493 Young Myeloma Patients Treated With Modern Therapies: A Canadian Myeloma Research Group Database Study.. 13:e70332. 2024
-
Virtual follow‐up care among breast and prostate cancer patients during and beyond the
COVID ‐19 pandemic: Association with distress. 13:e6948. 2024 - Describing settings of care in the last 100 days of life for cancer decedents: a population‐based descriptive study. 12:4809-4820. 2023
-
Patient‐reported outcomes in childhood head and neck rhabdomyosarcoma survivors and their relation to physician‐graded adverse events—A multicenter study using the
FACE‐Q Craniofacial module. 12:4739-4750. 2023 - Real‐world data on lenalidomide dosing and outcomes in patients newly diagnosed with multiple myeloma: Results from the Canadian Myeloma Research Group Database. 12:4357-4362. 2023
- Artificial neural networks for simultaneously predicting the risk of multiple co‐occurring symptoms among patients with cancer. 10:989-998. 2021
- Cabozantinib real‐world effectiveness in the first‐through fourth‐line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. 10:1212-1221. 2021
- The impact of routine Edmonton Symptom Assessment System (ESAS) use on overall survival in cancer patients: Results of a population‐based retrospective matched cohort analysis. 9:7107-7115. 2020
- Quality of adverse event reporting in phase III randomized controlled trials of breast and colorectal cancer: A systematic review.. 9:5035-5050. 2020
- Second‐line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real‐world eligibility for cabozantinib, regorafenib, and ramucirumab. 9:4640-4647. 2020
- Real‐world outcomes of FOLFIRINOX vs gemcitabine and nab‐paclitaxel in advanced pancreatic cancer: A population‐based propensity score‐weighted analysis. 9:160-169. 2020
- IL‐25 promotes cisplatin resistance of lung cancer cells by activating NF‐κB signaling pathway to increase of major vault protein. 8:3491-3501. 2019
- Economic evaluation of smoking cessation in Ontario's regional cancer programs. 7:4765-4772. 2018
- Prognosis of patients with hepatocellular carcinoma treated with sorafenib: a comparison of five models in a large Canadian database. 7:2816-2825. 2018
- Describing symptoms using the Symptom Screening in Pediatrics Tool in hospitalized children with cancer and hematopoietic stem cell transplant recipients. 7:1750-1755. 2018
- Treatment‐related mortality in newly diagnosed pediatric cancer: a population‐based analysis. 7:707-715. 2018
- StrandAdvantage test for early‐line and advanced‐stage treatment decisions in solid tumors. 6:883-901. 2017
- Association of dose escalation of octreotide long‐acting release on clinical symptoms and tumor markers and response among patients with neuroendocrine tumors. 4:864-870. 2015
-
Two
BRM promoter insertion polymorphisms increase the risk of early‐stage upper aerodigestive tract cancers. 3:426-433. 2014 - Reduction in serum clusterin is a potential therapeutic biomarker in patients with castration‐resistant prostate cancer treated with custirsen. 2:468-477. 2013
- A contemporary analysis of morbidity and outcomes in cytoreduction/hyperthermic intraperitoneal chemoperfusion. 2:334-342. 2013
-
Phase II study of
TAS ‐106 in patients with platinum‐failure recurrent or metastatic head and neck cancer and nasopharyngeal cancer. 2:351-359. 2013 - Early detection of clinically significant prostate cancer at diagnosis: a prospective study using a novel panel of TMPRSS2:ETS fusion gene markers.. 2:63-75. 2013